Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients

Clinical and Vaccine Immunology

Volumn 15, Issue 3, 2008, Pages 506-512

  Newton, Sandra M ^a   Mackie, Sarah L ^b,c   Martineau, Adrian R ^a   Wilkinson, Katalin A ^a,d   Kampmann, Beate ^a   Fisher, Corinne ^b,e   Dutta, Shouma ^b   Levin, Michael ^a   Wilkinson, Robert J ^a,d   Pasvol, Geoffrey ^a,b  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CYTOKINE; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; BACTERIAL PROTEIN; CHEMOKINE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BACTERIAL GENE; BACTERIAL IMMUNITY; BLOOD SAMPLING; CELL MIGRATION; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CYTOKINE RELEASE; GRANULOMA; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; INFECTION RISK; LOADING DRUG DOSE; LUMINESCENCE; LUX GENE; MAINTENANCE THERAPY; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TUBERCULOSIS; BIOASSAY; BLOOD; DOWN REGULATION; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL PROTEINS; BIOLOGICAL ASSAY; CHEMOKINES; DOWN-REGULATION; HUMANS; LUMINESCENCE; MIDDLE AGED; MYCOBACTERIUM BOVIS; SPONDYLITIS, ANKYLOSING; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42049109780     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00401-07     Document Type: Article

References (38)

1. Algood, H. M., J. Chan, and J. L. Flynn. 2003. Chemokines and tuberculosis. Cytokine Growth Factor Rev. 14:467-477.
2. Algood, H. M., P. L. Lin, and J. L. Flynn. 2005. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin. Infect. Dis. 41(Suppl. 3):S189-S193.
3. Algood, H. M., P. L. Lin, D. Yankura, A. Jones, J. Chan, and J. L. Flynn. 2004. TNF influences chemokine expression of macrophages in vitro and that of CD11b+ cells in vivo during Mycobacterium tuberculosis infection. J. Immunol. 172:6846-6857.
4. Andreakos, E. T., B. M. Foxwell, F. M. Brennan, R. N. Maini, and M. Feldmann. 2002. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev. 13:299-313.
5. Botha, T., and B. Ryffel. 2003. Reactivation of latent tuberculosis infection in TNF-deficient mice. J. Immunol. 171:3110-3118.
6. Boulman, N., M. Rozenbaum, G. Slobodin, and I. Rosner. 2006. Mycobacterium fortuitum infection complicating infliximab therapy in rheumatoid arthritis. Clin. Exp. Rheumatol. 24:723.
7. Brassard, P., A. Kezouh, and S. Suissa. 2006. Antirheumatic drugs and the risk of tuberculosis. Clin. Infect. Dis. 43:717-722.
8. Dinarello, C. A. 2005. Differences between anti-tumor necrosis factor-a monoclonal antibodies and soluble TNF receptors in host defense impairment. J. Rheumatol. Suppl. 74:40-47.
9. Ehlers, S. 2003. Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann. Rheum. Dis. 62(Suppl. 2):ii37-ii42.
10. Ehlers, S. 2005. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J. Rheumatol. Suppl. 74:35-39.
11. Feldmann, M., and R. N. Maini. 1999. The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 38(Suppl. 2):3-7.
12. Flynn, J. L., and J. Chan. 2001. Immunology of tuberculosis. Annu. Rev. Immunol. 19:93-129.
13. Flynn, J. L., M. M. Goldstein, J. Chan, K. J. Triebold, K. Pfeffer, C. J. Lowenstein, R. Schreiber, T. W. Mak, and B. R. Bloom. 1995. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561-572.
14. Gardam, M. A., E. C. Keystone, R. Menzies, S. Manners, E. Skamene, R. Long, and D. C. Vinh. 2003. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect. Dis. 3:148-155.
15. Giles, J. T., and J. M. Bathon. 2004. Serious infections associated with anticytokine therapies in the rheumatic diseases. J. Intensive Care Med. 19:320-334.
16. Islam, N., A. R. Kanost, L. Teixeira, J. Johnson, R. Hejal, H. Aung, R. J. Wilkinson, C. S. Hirsch, and Z. Toossi. 2004. Role of cellular activation and tumor necrosis factor-alpha in the early expression of Mycobacterium tuberculosis 85B mRNA in human alveolar macrophages. J. Infect. Dis. 190:341-351.
17. Kampmann, B., P. O. Gaora, V. A. Snewin, M. P. Gares, D. B. Young, and M. Levin. 2000. Evaluation of human antimycobacterial immunity using recombinant reporter mycobacteria. J. Infect. Dis. 182:895-901.
18. Keane, J. 2005. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 44:714-720.
19. Keane, J. 2004. Tumor necrosis factor blockers and reactivation of latent tuberculosis. Clin. Infect. Dis. 39:300-302.
20. Keane, J., S. Gershon, R. P. Wise, E. Mirabile-Levens, J. Kasznica, W. D. Schwieterman, J. N. Siegel, and M. M. Braun. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345:1098-1104.
21. Kindler, V., A. P. Sappino, G. E. Grau, P. F. Piguet, and P. Vassalli. 1989. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56:731-740.
22. Klimiuk, P. A., S. Sierakowski, I. Domyslawska, and J. Chwiecko. 2006. Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 24:529-533.
23. Mohan, V. P., C. A. Scanga, K. Yu, H. M. Scott, K. E. Tanaka, E. Tsang, M. M. Tsai, J. L. Flynn, and J. Chan. 2001. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect. Immun. 69:1847-1855.
24. Mufti, A. H., B. W. Toye, R. R. McKendry, and J. B. Angel. 2005. Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use. Diagn. Microbiol. Infect. Dis. 53:233-238.
25. Nestorov, I., M. I. Sadek, E. Sada, Z. Toossi, S. K. Schwander, E. A. Rich, C. Ameixa, and J. S. Friedland. 2005. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin. Arthritis Rheum. 34(Suppl 1):12-18.
26. Okubo, H., M. Iwamoto, T. Yoshio, H. Okazaki, T. Kato, M. Bandoh, and S. Minota. 2005. Rapidly aggravated Mycobacterium avium infection in a patient with rheumatoid arthritis treated with infliximab. Mod. Rheumatol. 15:62-64.
27. Popa, C., M. G. Netea, P. Barrera, T. R. Radstake, P. L. van Riel, B. J. Kullberg, and J. W. Van der Meer. 2005. Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy. Cytokine 30:72-77.
28. Roach, D. R., A. G. Bean, C. Demangel, M. P. France, H. Briscoe, and W. J. Britton. 2002. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol. 168:4620-4627.
29. Saliu, O. Y., C. Sofer, D. S. Stein, S. K. Schwander, and R. S. Wallis. 2006. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J. Infect. Dis. 194:486-492.
30. Saunders, B. M., and A. M. Cooper. 2000. Restraining mycobacteria: role of granulomas in mycobacterial infections. Immunol. Cell Biol. 78:334-341.
31. Snewin, V. A., M. P. Gares, P. O. Gaora, Z. Hasan, I. N. Brown, and D. B. Young. 1999. Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect. Immun. 67:4586-4593.
32. Tena, G. N., D. B. Young, B. Eley, H. Henderson, M. P. Nicol, M. Levin, and B. Kampmann. 2003. Failure to control growth of mycobacteria in blood from children infected with human immunodeficiency virus and its relationship to T cell function. J. Infect. Dis. 187:1544-1551.
33. Tessier, P. A., P. H. Naccache, I. Clark-Lewis, R. P. Gladue, K. S. Neote, and S. R. McColl. 1997. Chemokine networks in vivo: involvement of C-X-C and C-C chemokines in neutrophil extravasation in vivo in response to TNF-alpha. J. Immunol. 159:3595-3602.
34. Tufariello, J. M., J. Chan, and J. L. Flynn. 2003. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect. Dis. 3:578-590.
35. Wallis, R. S., M. S. Broder, J. Y. Wong, M. E. Hanson, and D. O. Beenhouwer. 2004. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 38:1261-1265.
36. Wallis, R. S., and S. Ehlers. 2005. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin. Arthritis Rheum. 34:34-38.
37. Wilkinson, R. J., L. E. DesJardin, N. Islam, B. M. Gibson, R. A. Kanost, K. A. Wilkinson, D. Poelman, K. D. Eisenach, and Z. Toossi. 2001. An increase in expression of a Mycobacterium tuberculosis mycolyl transferase gene (fbpB) occurs early after infection of human monocytes. Mol. Microbiol. 39:813-821.
38. Wolfe, F., K. Michaud, J. Anderson, and K. Urbansky. 2004. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 50:372-379.